Announcements Trials
Browse Landscape

Phase

Phase 3 36Phase 2 25Phase 1/2 12Phase 2/3 5Phase 1 5

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Gastrointestinal 2Dermatologic 1Breast 1

Conditions

Neoplasms 2Lung Neoplasms 2Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1Melanoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Specimen Handling 98Biopsy 69Magnetic Resonance Spectroscopy 63pembrolizumab 46Cyclophosphamide 43fludarabine 38Carboplatin 22venetoclax 19Nivolumab 18Cetuximab 18Bevacizumab 17Radiotherapy 16fludarabine phosphate 15Cisplatin 15X-Rays 14Ipilimumab 13Fluorouracil 13Cytarabine 13Temozolomide 12Leucovorin 12Irinotecan 12atezolizumab 11Radiation 11Paclitaxel 11Azacitidine 11durvalumab 10Oxaliplatin 10Injections 10Gemcitabine 10Dexamethasone 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Docetaxel × 30 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT07316686 2026-05-18

Lutécio

Instituto do Cancer do Estado de São Paulo

Phase 1 Not yet recruiting
18 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
290 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡